Now, that account is worth $55,000, with a 65% concentration in Nvidia (NVDA), which was my first stock buy, then a 20% concentration in Novo Nordisk (NVO) and Eli Lilly (LLY) stock, with 15% ...

Oscar-winning filmmaker Ezra Edelman's Prince project is joining a select list of documentaries with a dubious distinction – ...

The Vanguard Mega Cap ETF is outperforming the S&P 500 but lagging peers like XLG and OEF. Read more on the analysis of MGC ...

A former NFL linebacker was sentenced in Los Angeles on Monday for running a Ponzi Scheme that defrauded his victims of $5.3 ...

Bristol Myers Squibb and Alexandria Real Estate are top picks for the income-focused, offering high dividends and growth ...

BENNINGTON — Vermont Arts Exchange (VAE) and its Basement Music Series, is bringing The Mammals back to Bennington on ...

Singer Lily Allen and David Harbour have reportedly called it quits on their four-year marriage after months of speculation that their relationship was on the rocks. Allen, 39, and Harbour ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...

Eli Lilly LLY-2.01%decrease; red down pointing triangle is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using their health plans ...

Eli Lilly is buying a new drug and lowering prices on an existing one. GLP-1 weight loss drug Zepbound is getting cheaper. This will make Lilly's product relatively more attractive, and help to ...

INDIANAPOLIS, Feb. 25, 2025 /PRNewswire/ -- Today Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from ...